Name | 3-(2,5-dioxopyrrol-1-yl)-5-hydroxy-2,2-bis(2-hydroxyethyl)pentanoic acid |
---|---|
Synonyms |
Maleimido-Tri(EthyleneGlycol)-PropionicAcid
1H-Pyrrole-1-propanoic acid, 2,5-dihydro-α,α,β-tris(2-hydroxyethyl)-2,5-dioxo- 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-hydroxy-2,2-bis(2-hydroxyethyl)pentanoic acid 3-(2-(2-(2-(2,5-dioxo-2H-pyrrol-1(5H)-yl)ethoxy)ethoxy)ethoxy)propanoic acid MAL-PEG3-COOH |
Description | Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-specific cysteine mutant trastuzumab-A114C conjugation[1]. |
---|---|
Related Catalog | |
Target |
Cleavable |
In Vitro | Mal-PEG3-C2-acid can be used to synthesis linker-payload 16 (compound 15) and 20 (compound 18). linker-payload 16 amd 20 is conjugated to DAR1.9 and DAR1.7[1]. ADC 23 and 24 are Neolymphostin ADCs that composes of DAG 1.9 and DAG1.7 linked to PIKK inhibitors with linker-payload 16 and 20, respectively[1]. ADC24 demonstrates cytotoxic activity against BT474 and N87 cell lines with IC50 of 195 and 202 nM, respectively[1]. ADC23 demonstrates cytotoxic activity against BT474 and N87 cell lines with IC50 of 286 and 274 nM, respectively[1]. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 634.2±55.0 °C at 760 mmHg |
Molecular Formula | C13H19NO7 |
Molecular Weight | 301.293 |
Flash Point | 337.3±31.5 °C |
Exact Mass | 301.116150 |
PSA | 135.37000 |
LogP | -1.29 |
Vapour Pressure | 0.0±4.2 mmHg at 25°C |
Index of Refraction | 1.597 |
~% 518044-40-1 |
Literature: Bayer Intellectual Property GmbH; Lerchen, Hans-Georg; Linden, Lars; El Sheikh, Sherif; Willuda, Jörg; Kopitz, Charlotte Christine; Schuhmacher, Joachim; Greven, Simone; Mahlert, Christoph; Stelte-Ludwig, Beatrix; Golfier, Sven; Beier, Rudolf; Heisler, Iring; Harrenga, Axel; Thierauch, Karl-Heinz; Bruder, Sandra; Petrul, Heike; Jörissen, Hannah; Borkowski, Sandra Patent: US2013/66055 A1, 2013 ; Location in patent: Page/Page column ; Title/Abstract Full Text Show Details Bayer Pharma Aktiengesellschaft; Bayer Intellectual Property GmbH; Lerchen, Hans-Georg; Linden, Lars; Sheikh, Sherif El; Willuda, Jörg; Kopitz, Charlotte C.; Schuhmacher, Joachim; Greven, Simone; Mahlert, Christoph; Stelte-Ludwig, Beatrix; Golfier, Sven; Beier, Rudolf; Heisler, Iring; Harrenga, Axel; Thierauch, Karl-Heinz; Bruder, Sandra; Petrul, Heike; Jörißen, Hannah; Brokowski, Sandra Patent: US2014/127240 A1, 2014 ; Location in patent: Page/Page column ; |
~% 518044-40-1 |
Literature: Bayer Intellectual Property GmbH; Lerchen, Hans-Georg; Linden, Lars; El Sheikh, Sherif; Willuda, Jörg; Kopitz, Charlotte Christine; Schuhmacher, Joachim; Greven, Simone; Mahlert, Christoph; Stelte-Ludwig, Beatrix; Golfier, Sven; Beier, Rudolf; Heisler, Iring; Harrenga, Axel; Thierauch, Karl-Heinz; Bruder, Sandra; Petrul, Heike; Jörissen, Hannah; Borkowski, Sandra Patent: US2013/66055 A1, 2013 ; Title/Abstract Full Text Show Details Bayer Pharma Aktiengesellschaft; Bayer Intellectual Property GmbH; Lerchen, Hans-Georg; Linden, Lars; Sheikh, Sherif El; Willuda, Jörg; Kopitz, Charlotte C.; Schuhmacher, Joachim; Greven, Simone; Mahlert, Christoph; Stelte-Ludwig, Beatrix; Golfier, Sven; Beier, Rudolf; Heisler, Iring; Harrenga, Axel; Thierauch, Karl-Heinz; Bruder, Sandra; Petrul, Heike; Jörißen, Hannah; Brokowski, Sandra Patent: US2014/127240 A1, 2014 ; |
Precursor 3 | |
---|---|
DownStream 0 |